Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation

1Hemorrhagic transformation (HT) is a common complication of ischemic stroke that is often exacerbated by reperfusion with alteplase (recombinant tissue plasminogen activator) or endovascular therapy (EVT). It occurs when the blood-brain barrier (BBB) is sufficiently disrupted to permit extravasation of peripheral blood into the brain. When HT occurs, it increases stroke morbidity and mortality and thus is important to prevent.

2HT can be identified in 3–40% of patients with ischemic stroke, depending on the definition used and the characteristics of the cohort studied. HT is classified using both clinical and radiological criteria as summarized in Table 1. Clinical classification distinguishes symptomatic intracranial hemorrhage (sICH) from asymptomatic intracranial hemorrhage (aICH). sICH is defined as a worsening of the National Institutes of Health Stroke Scale (NIHSS) by ≥4 points within the first 36 h of stroke onset that is attributable to HT. A limitation of the clinical classification is that HT may be missed if it does not result in a major worsening of the neurological status. This may be the case when reperfusion therapy improves the NIHSS and offsets potential worsening caused by HT. The radiological classification of HT arose from the European Cooperative Acute Stroke Study (ECASS) and distinguishes small petechial hemorrhagic infarction (HI1), confluent petechial hemorrhagic infarction (HI2), small parenchymal hemorrhage (PH1) (<30% of infarct, mild mass effect), and large parenchymal hemorrhage (PH2, >30% of infarct, marked mass effect). The ECASS definition has fairly poor intra- and inter-rater agreement for all types/categories except large PH2. A Heidelberg Bleeding Classification scale has been proposed to address some of the challenges and limitations of the ECASS classification.

3A challenge with clinical and radiological classifications of HT is that they lack specificity to the underlying mechanism of BBB disruption and HT. Details of the mechanism of BBB disruption and the cause of HT might be included in future classification systems as our understanding of the processes involved in HT evolves. Figure 1 provides a schematic of the discussed immune pathways contributing to HT in ischemic stroke.

4Inflammation and immune system activation are important contributors to BBB disruption and HT. In acute stroke activated neutrophils and monocytes produce reactive oxygen species (ROS) and matrix metalloproteinases (MMP-9, MMP-2) that contribute to BBB disruption and HT. Microglia, astrocytes, and endothelial cells also contribute to BBB disruption and HT through the production of MMPs, proteases, vascular remodeling, and neuroinflammation (Table 2). In the following sections, we discuss how the immune system contributes to HT specifically in the context of clinical factors related to HT, notably stroke severity, reperfusion, hypertension, diabetes, and age.

5Several trials have focused on improving stroke outcomes through targeting immune factors. There has yet to be immunomodulator identified to reduce the risk of HT. A summary of discussed treatments and their molecular targets is provided in Table 3.

6Clinical features associated with an increased risk of HT in patients with ischemic stroke include advanced age, stroke severity (NIHSS), hypertension, hyperglycemia, poor collaterals, early infarction on brain imaging, low platelet count, use of antithrombotic drugs, and reperfusion therapy. Many of these factors are associated with inflammation and activation of the immune system, as discussed below. The clinical features have been summarized into scores to estimate the risk of HT and guide reperfusion therapy (Table 4). However, clinical characteristics and risk scores fail to identify all patients who experience HT, highlighting that a gap remains in our understanding of the pathophysiology of HT. Variables most commonly included in HT risk scores are stroke severity (admission NIHSS), hyperglycemia, hypertension, and age.

7There is a strong relationship between duration and severity of brain ischemia and the risk of HT in both patients with stroke and experimental stroke models. Increased time from stroke onset is associated with larger core volumes, a higher degree of vascular disruption, and therefore a higher risk of HT. Increased time from ischemia onset to reperfusion has been associated with an increased risk of HT whether they received thrombolytic therapy or not. Recanalization beyond 6 h of stroke onset is an independent predictor of HT in human stroke, while early reperfusion is associated with a reduced risk of HT. Increased NIHSS is also associated with risk of HT. Patients with an NIHSS < 10 had <13% rate of HT. In comparison, patients with NIHSS > 15 had >50% rate of HT. Activation of the immune system is related to severity of infarction. Whether the greater immune activation from a larger infarct increases risk of HT remains unclear and warrants further evaluation.

8Treatment with alteplase is associated with a 6–8% risk of sICH. This is mediated in part by the fact that thrombolytics breakdown blood clots and recanalize occluded cerebral vasculature. Recanalization of an occluded blood vessel can promote BBB disruption, contributing to reperfusion injury and increased risk of HT. Activation of platelets, coagulation factors, and the innate and adaptive immune systems also contribute to injury following restoration of blood flow.

9Alteplase can also promote HT through non-fibrinolytic mechanisms, including activation of the immune system. Alteplase promotes neutrophil degranulation and release of MMP-9. It acts on protease-activated receptor 1 (PAR-1) to increase MMP-9 expression and disrupt the BBB. Additionally, alteplase activates platelet-derived growth factor-CC (PDGF-CC), an agonist of platelet-derived growth factor receptor alpha (PDGFRa) on astrocyte end-feet. This can promote BBB disruption and HT, as PDGFRa activates MMPs. Alteplase also binds the lipoprotein receptor (LRP) on neurons and perivascular astrocytes to induce MMP-3 and MMP-6 expression. While inhibition of MMPs can reduce the risk of HT in animal stroke models, evidence in humans is lacking. Minocycline inhibits MMP-9 and has been evaluated in the MINOS trial. A phase 4 trial was later terminated due to lack of effect. MMP-9 inhibition, while potentially beneficial to reduce the risk of HT, may also impair post-stroke vascular remodeling and impair recovery. Indeed, inhibition of MMP-9 at 24–48 h after stroke worsens outcome in animal models. A phase 2 study, SAFE-TPA, evaluated different doses of Otaplimastat, a neuroprotectant inhibiting the MMP pathway. In animal models, Otaplimastat in combination with alteplase helped to reduce edema and HT. While Kim et al. found the drug to be safe in patients, further investigation is required to determine effect in stroke.

10Evidence is emerging regarding the use of Tenecteplase (TNK) in acute ischemic stroke, a current treatment for acute myocardial infarction. TNK promotes the conversion of plasminogen to plasmin which degrades fibrin-based clots. It is a variant of recombinant tPA (tissue plasminogen activator), with higher resistance to plasminogen activator inhibitor-1 (PAI-1) and enhanced fibrin specificity. Studies of TNK in stroke are ongoing. In the EXTEND-IA TNK Trial, recanalization rates before thrombectomy were higher in the TNK group (22%, n = 101) compared with the alteplase group (10%, n = 101) with improved functional outcomes and similar risk of HT (1% sICH and 5–6% HT PH2). As with alteplase, TNK may promote HT through several mechanisms that warrant further investigation.

11Experimental evidence supports a role of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in early HT. Superoxide and peroxynitrite can disrupt microvascular integrity and may contribute to HT. Cerbral ischemia and reperfusion produce reactive oxygen and nitrogen species including superoxide, nitric oxide (NO), and peroxynitrite (ONOO−) in microvessels, neurons and astrocyte end feet. Peroxynitrite can activate MMPs further disrupting vascular integrity. Hyperglycemia, as described in the section Hyperglycemia and HT can also enhance ROS and peroxynitrite.

12High-mobility group box 1 (HMGB1) is released from injured cells of the central nervous system such as microglia and astrocytes. HMGB1 binds to its receptors (RAGE, toll-like receptor 2 (TLR2), and TLR4) and augments inflammation via the upregulation of tumor necrosis factor (TNF), interleukin 1β (IL-1β), and other cytokines. HMGB1 upregulates MMP-9 in neurons and astrocytes via TLR4. This could be a proposed target to help dampen the inflammatory response in cerebral ischemia and prevent HT as discussed in the section Hyperglycemia and HT.

13Nuclear factor-κB (NF-κB) acts as a complex regulator of the innate immune system leading to activation of cellular adhesion molecules such as ICAM-1, VCAM-1 and E-selectin and inflammatory cytokines, mediating the neutrophil infiltration pathway. A study targeting HIF-1, hypoxia-inducible factor 1, a transcription factor that works to maintain homeostasis under hypoxia, found that BBB integrity was protected through suppressing the HMGB1/TLR4/NF-κB pathway to reduce the risk of alteplase-induced HT.

14In experimental studies, Enlimomab, an ICAM-1 antibody, reduced leukocyte adhesion and infarct size. In the Enlimomab Acute Stroke Trial, it was associated with poor outcomes and increased HT.

15In the RHAPSODY phase 2 trial, 3K3A-APC (a modified APC), a recombinant variant of human activated protein C (part of the coagulation pathway), was evaluated as a neuroprotectant in acute ischemic stroke treated with alteplase and or mechanical thrombectomy. 3K4A-APC acts on the protease-activated receptor 1 (PAR1) to promote vascular integrity and reduce neurological injury. The study showed a trend toward reduced HT, but further confirmation is required. However, targeting the PAR1 receptor shows promise as a strategy to reduce HT in stroke patients treated with reperfusion therapy.

16Endovascular thrombectomy is of benefit in patients with acute large vessel occlusion and salvageable brain tissue. In a metanalysis of SWIFT PRIME, ESCAPE, EXTEND-IA, and REVASCAT the risk of sICH was 2.5% in EVT treated compared to 2.8% in non-EVT treated patients (p = 0.76), and the risk of PH was 8% in both EVT-treated patients and non-EVT patients (p = 0.96). In the HERMES pooled analysis of MR CLEAN, ESCAPE, REVASCAT, SWIFT PRIME, and EXTEND IA stroke trials, the rate of sICH was 4.4% in the EVT group compared to 4.3% in the medical therapy group. Thus, the rate of HT is not significantly higher in the patients enrolled in EVT trials compared to controls receiving alteplase alone.

17The DIRECT-MT trial compared EVT-only to EVT plus alteplase. The rates of HT were comparable between groups, with sICH occurring 4.3% in EVT group vs. 6.1% in EVT + alteplase (p = 0.30) and aICH occurring in 33.3% of the EVT group 36.2% in the EVT + alteplase group (p0.45). Similar rates of HT in EVT + alteplase vs. EVT alone have been reported by others.

18Thus, reperfusion with EVT may have lower rate of sICH than might be expected. EVT can provide a more rapid recanalization of large vessel occlusions which may reduce severity of ischemic brain injury, and thus reduce risk of HT. This is particularly true when EVT-treated patients are selected for small core and large penumbra by imaging. Core size does relate to risk of HT, with HT being higher in EVT-treated patients with larger core on baseline imaging. EVT may also produce differences in the type BBB disruption compared to alteplase. In an animal model, alteplase produced a more diffuse pattern of BBB disruption, whereas EVT had a more concentrated BBB disruption in central areas of ischemia. Additional evaluation is needed to understand HT in EVT-treated patients including differences in BBB disruption and potential benefits and risks of rt-PA (alteplase) use before EVT.

19Hyperglycemia is present in approximately 28–40% of patients with acute ischemic stroke. It can relate to pre-existing diabetes mellitus (DM) or a stress response leading to a rise in cortisol, glucose and catecholamines. For both diabetic and non-diabetic patients, hyperglycemia increases the risk of HT and is associated with worse clinical outcomes. There are conflicting reports concerning infarct growth in a hyperglycemic setting relative to normal glycemic levels. For the most part, hyperglycemia is associated with more rapid infarct growth and worse outcomes. In a review of 426 patients, higher values of HbA1c were associated with a higher risk of HT in patients with fasting blood glucose > 7.8 mmol/L (27% higher risk) and in those with fasting blood glucose <7.8 mmol/L (36% higher risk). Higher levels of HbA1c were also associated with a 48% higher risk of poor functional outcome. Treatment of hyperglycemia is recommended by stroke guidelines for the management of patients with acute ischemic stroke. Hyperglycemia is a risk factor for HT in both alteplase-treated patients and those not receiving thrombolysis. This association might be driven by hyperglycemia's effects on brain vasculature and the inflammatory response.

20Hyperglycemia can potentiate inflammation resulting in increased BBB disruption and HT. Factors related to hyperglycemia that can increase the risk of HT are presented in Table 5. Diabetes is associated with an increase in plasma TNF, IL-1β, interleukin 6 (IL-6), interferon-g (IFNγ), and PAI-1, as well as alteration in immune cell response leading to chronic low-grade inflammation. An increase in PAI-1 may decrease the efficacy of alteplase and increase infarct size. This may result in increased risk of HT. Hyperglycemia also activates nuclear factor-κB (NF-κB) in astrocytes, and enhances leukocyte adhesion through higher expression of cell adhesion molecules in cerebral blood vessels (ICAM1, intracellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule 1 and E-selectin) and the production of pro-inflammatory cytokines (TNF, IL-6, and IL-1β).

21Neutrophils from patients with diabetes have enhanced capacity for endothelial adhesion. In stroke models using diabetic rats, hyperglycemia increases neutrophil adhesion and transmigration, and also increases expression of TNF, IL-1β, E-selectin, soluble intercellular adhesion molecules (sICAMs), endothelial NO synthase (eNOS) and inducible nitric oxide synthase (iNOS). In a rat model, hyperglycemia increases infarct volume, worsens outcome and increases risk of HT. Additionally, hyperglycemia increased the activity of MMP-9. Risk of HT is increased by glucose injection regardless of the time of ischemia. Hyperglycemia can also increase superoxide production through NADPH oxidase, resulting in greater BBB disruption and HT. Apocynin, an NADPH oxidase inhibitor, prevents BBB disruption and HT in animal models of stroke.

22In a rat model of stroke, hyperglycemia enhanced release of HMGB1 and the rate of alteplase related HT. Treatment with glycyrrhizin, a direct HMBG1 inhibitor, downregulated the expression of NADPH. This decreased superoxide and peroxynitrite(ONOO−), reduced TLR2, and MMP-9, and preservation of type IV collagen and claudin-5, thus attenuating HT and BBB damage. The role of an HMGB1 inhibitor in patients with stroke remains to be determined.

23NLRP3 (NOD-like receptor protein 3) inflammasome can also promote BBB disruption and HT. In a MCAO rat model with acute hyperglycemia and increased expression of NADPH oxidase, iNOS induction lead to the production of superoxide, nitric oxide and peroxynitrite. It was suggested that peroxynitrite could activate NLRP3 inflammasome in hyperglycemia, a mediator in HT following reperfusion. Inhibiting the NLRP3 inflammasome minimized HT in vivo, and could potentially offer a treatment option.

24NLRP3 inflammasome is also involved in chronic inflammation associated with type 2 diabetes (T2DM). Primary activation of NLRP3 leads to transcription of pro-IL-1β and pro-IL-18 into mature IL-1β and IL-18. Active IL-1β is then responsible for increased expression of adhesion molecules, leading to neutrophil recruitment and contributing to BBB disruption. Inhibiting NLRP3 may reduce the impact of stroke in patients with diabetes by regulating neutrophil recruitment. Hyperglycemia may upregulate TXNIP-NLRP3 inflammasome causing alteplase induced BBB disruption and HT. Thioredoxin interacting protein (TXNIP) mediates hyperglycemia-induced oxidative damage and inflammation in the brain, while reducing cerebral glucose uptake/utilization.

25Other mechanisms by which hyperglycemia can promote BBB disruption and cause HT include a decrease in tight junction proteins occludin and claudin-5, chronic oxidative stress and thickening of microvascular basement membrane, increase of microvascular permeability, and loss of pericytes.

26Hyperglycemia impairs the fibrinolytic activity of alteplase, particularly in the acute phase of treatment, which may result in larger infarct size with more severe ischemia and thus, higher risk of HT. Type 2 DM is associated with increased blood levels of PAI-1, an inhibitor of tPA (endogenous and exogenous). Hyperglycemia also affects the coagulation system by increasing thrombin production and stimulating the intrinsic tissue factor pathway, thus affecting reperfusion and contributing to HT. In rats with Type 1 DM, treatment of acute stroke with alteplase increased MMP-9 activity, BBB breakdown, brain hemorrhage, and worsened functional outcomes.

27Several stroke trials have evaluated the benefit of treating hyperglycemia to reduce the risk of HT. Control of hyperglycemia through insulin infusion was tested in patients in the UK Glucose Insulin in Stroke Trial (GIST UK) and the SHINE trial. In the SHINE trial, 80% of the patients had Type 2 DM. In the intensive treatment group, the average blood glucose was 6.6 mmol/L compared to 9.9 mmol/L in the standard treatment group. No net improvement in stroke outcome was identified, despite a significant reduction in blood glucose achieved with insulin infusion. Potential acute lowering of glucose does not fully mitigate downstream effects already initiated by hyperglycemia such as enhanced inflammation, endothelial cell dysfunction, neutrophil adhesion, MMP-9 activity, and ROS production. There is an ongoing secondary analysis of the effect of acute insulin therapy on the risk of HT, which may provide further insights into the link between hyperglycemia and HT from the SHINE trial.

28A systematic review of 274 research articles aimed to identify the ideal target and strategy for blood glucose management. Glucose control was recommended to start within the first few hours of stroke onset. Tight glucose control was not recommended due to the risk of hypoglycemic events. Glycemic variability is to be avoided, as it is associated with adverse outcomes.

29An elevated blood pressure can increase the risk of HT through a variety of mechanisms, including direct mechanical effects on the cerebral/brain vasculature, exacerbated inflammation, and vascular remodeling affecting collateral circulation, endothelial function, and autoregulation. A summary of factors in hypertension that impacted HT through BBB modification is shown in Table 6.

30Hypertension is common in patients with ischemic stroke and associated with increased risk of HT. Blood pressure is elevated in over 60% of patients with acute stroke. The elevated blood pressure may be caused by several components, including pre-existing or untreated hypertension, stress response (transient response), increased intracranial pressure, disrupted central autonomic regulation, activation of the neuroendocrine system, or inflammatory responses.

31Hypertension is associated with disruption of the BBB which could increase risk of HT. In the spontaneous hypertensive rat, BBB disruption can be observed as early as 3 months of age. The renin-angiotensin system is involved in hypertension and contributes to BBB disruption. It activates MMPs, causing an increase in circulating and tissular MMP-2 and MMP-9. The increase of angiotensin II in hypertension induces perivascular macrophages to produce ROS and contribute to BBB disruption. Hypertension is associated with an increase in blood levels of pro-inflammatory cytokines such as TNF, IL-6, monocyte chemoattractant protein-1(MCP-1), and sICAM-1 which can contribute to BBB disruption. Hypertension is associated with a decreased expression of cerebral endothelial tight junction proteins (claudin-3, claudin-5, and claudin-12), thus enhancing BBB permeability. Angiotensin II causes an increase in serum PAI-1 levels, thus reducing the effectiveness of alteplase.

32Chronic hypertension alters the cerebral vasculature, with microvascular rarefaction, arterial remodeling, and increased BBB permeability. Hypertension is associated with a decrease in lumen diameter, increase in vascular resistance, and impairment of endothelial function. These effects impair collateral circulation, reducing capacity to maintain adequate oxygenation when a cerebral artery occlusion occurs. Poor collateral circulation, which sustains the penumbra, results in faster expansion of infarct core, associated with risk of HT.

33In a rabbit clot model, hypertension induced before and after alteplase administration increases the risk of HT. The size of HT also relates to the peak mean arterial blood pressure. Decreasing pre-stroke blood pressure in rats reduced the risk of HT. BBB changes may be mechanical or result from acute changes related to endothelial or inflammatory activation.

34Maintaining the blood pressure below 185/110 mmHg is recommended to reduce the risk of HT in patients treated with alteplase. The risk of HT increases with each 10 mmHg rise in systolic blood pressure from 140 to 180 mmHg. Observational studies suggest lower blood pressure within the first 24 h is associated with more favorable outcomes and less frequent sICH. In addition, the risk of HT following alteplase is higher in patients with greater blood pressure variability, particularly in the first 6 h, and in patients with elevated systolic blood pressure. An elevated systolic blood pressure (SBP) is also associated with worse outcomes and higher risks of HT in patients treated with EVT.

35The ENCHANTED trial compared the benefit of intensive blood pressure control (SBP target of 130–140 mmHg) to that of the standard of care (SBP <180 mmHg). Intensive lowering of blood pressure was safe and decreased the incidence of HT from 18.7 to 14.8% (p = 0.0137). However, despite a reduction in HT, no net improvement in the 90-day Modified Rankin Scale (mRS) was observed. The best stroke outcomes are observed when BP is maintained between 140 and 180 mmHg. It is challenging to understand the ideal blood pressure for stroke treatment. In an acute setting, a rise in BP may be beneficial for preservation of brain perfusion in case of large vessel occlusion (opening of collateral vessels) while intensive BP lowering in the hyperacute phase (<48 h) may be detrimental in the context of impaired regulation of the cerebral circulation. The RIGHT-2 trial showed that functional outcomes were not improved with blood pressure reduction prior to stroke treatment. The Dutch ThRombolysis in Uncontrolled Hypertension (TRUTH) trial is an ongoing study evaluating whether actively lowering blood pressure below 185/110 mmHg affects stroke outcome in alteplase treated patients.

36The BP-TARGET aimed to evaluate intense systolic blood pressure targets (100–129 mm Hg) and standard care systolic targets (130–185 mm Hg) for 24 h after reperfusion. Intensive blood pressure control was not superior to standard of care for the prevention of HT. A comment letter suggest that alternative variables should also be considered, such as collateral circulation, blood pressure variability at baseline and during monitoring.

37Advancing age is associated with an increased risk of HT, as well as worse stroke outcomes. Infarct size is not consistent between sources; however, most authors suggest an increase in infarct size. Despite an increased risk, patients of older age derive similar benefit from thrombolysis. The rationale for age to increase the risk of HT is multifactorial, including an increase in systemic inflammation and BBB permeability. Additionally, elderly patients are also more likely to be on antithrombotic treatment, have a greater burden of cerebrovascular disease, and are more likely to have comorbid diseases such as hypertension and diabetes. These comorbidities contribute to inflammation, notably atherosclerosis, diabetes, hypertension, and hyperlipidemia. When stroke occurs, this age-associated inflammation may contribute to BBB disruption leading to an increased risk of HT. Table 7 summarizes the mechanisms through which age affects the risk of HT.

38Advanced age is characterized by immunosenescence, gradual immune dysregulation and changes to cell function, leading to a reduced capacity to respond to antigen stimulation. Aging is also associated with inflammaging: chronic inflammation with elevated plasma concentrations of TNF, IL-1β, and IL-6 predictive of fragility, mortality, and functional disability. This chronic low-grade inflammation state alters the innate immunity of the brain and may contribute to the risk of HT.

39Aging impacts both the innate and adaptive immune systems. Over time, the availability of hematopoietic stem cells declines, leading to decreased capacity to renew peripheral immune cells. Fewer naive B-lymphocytes are produced from the bone marrow, and T cell diversity is also reduced after age 70. Cells of the myeloid lineage are also affected by age, neutrophils have decreased phagocytic capacity and a reduced oxidative burst, leading to an increased inflammatory time period. Moreover, there is reduced production of cytokines from macrophages which have decreased phagocytic capacity. During stroke, young mice tend to recruit monocytes, whereas aged mice have greater recruitment of neutrophils. Additionally, higher levels of ROS and MMP-9 are associated with increased age. As discussed in the section Inflammatory Biomarkers and Prediction of HT, an increased neutrophil to leukocyte (NIL) ratio was independently associated with HT. Furthermore, with advancing age, microglia may become more prone to generate an inflammatory response when stroke occurs. With advancing age, there is a dysregulation in microglia pathways leading to a prolonged and amplified immune response, thus potentially increasing the risk of HT.

40The neurovascular unit also undergoes age-related changes which may contribute to the risk of HT. Aged cerebral endothelial cells have a smaller cytoplasm and dysfunctional mitochondria that adopt a senescent phenotype, promoting low-grade inflammation. Endothelial cells also produce more ROS with age, which reduces NO activity and limits the vasodilation capacity. Moreover, the number of pericytes, vital for BBB integrity, decreases with age, with a negative impact on the microcirculation, reducing the ability to maintain the BBB integrity after stroke. Astrocytes can become more inflammatory with age, which may also contribute to the risk of HT. Additionally, astrocytes undergo clasmatodendrosis with age and retract their end-feet, thus altering BBB integrity. Finally, with aging, miRNA and RNA expression for genes associated with vascular tone, tight junction protein expression and cell adhesion are downregulated, impacting the BBB.

41Angiogenesis is a necessary process to reduce infarct volume and support recovery after stroke. The most critical factors for supporting capillary angiogenesis include fibroblast growth factor (FGF), TNF, transforming growth factor-beta (TGF-β), and the angiopoietins (Ang). With age, there is an attenuated pro-angiogenic response, decreased expression of vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1) possibly contributing to the risk of HT. VEGF has an important role in vascular remodeling and angiogenesis and is associated with delayed HT and vascular remodeling. VEGF has a biphasic role in stroke. Early after stroke, VEGF promotes BBB disruption and HT but supportes vascular function and BBB integrity at a later stage. In rats, VEGF signal inhibition attenuates alteplase-related HT. Age is associated with a decrease in the number and diameter of native collaterals as well as impaired collateral remodeling in the brain. Collaterals influence the rate of HT after thrombolytic treatment. Thus, the increased risk of HT with age may also relate to an age-associated reduction in collaterals.

42Several protein and transcription biomarkers have been evaluated to predict the risk of HT. This includes plasma cellular-fibronectin (c-Fn), a major component of extracellular matrix involved in wound healing and cell adhesion; MMPs; neutrophil and lymphocyte counts; ferritin, vascular adhesion molecule−1 (VAP-1), and IL-10 that are associated with alteplase induced HT. Additionally, inflammatory markers such as TNF, C-reactive protein and homocysteine are associated with the risk and severity of HT. Fibrinolysis inhibitors [PAI-1, lipoprotein(a), thrombin-activated fibrinolysis inhibitor (TAFI), and homocysteine] may help to predict sICH after thrombolysis.

43Ischemic stroke elicits a strong local and peripheral inflammatory response. There is an increase in inflammatory cytokines (e.g., TNF, IL-1β, IL-6), cell adhesion molecules (e.g., ICAM-1, VCAM, P-selectin), damage-associated molecular patterns [DAMPs, e.g., high mobility group box protein 1 (HMGB1), peroxiredoxin, mitochondrial DNA], MMPs and ROS. Microglia, cerebral endothelial cells, and peripheral leukocytes are also activated during the immune response. This results in the recruitment, adhesion, and infiltration of the ischemic brain by peripheral leukocytes. Aspects of the inflammatory response alters the structure of the BBB, reorganizing tight junction proteins and the actin cytoskeleton, and contributing to HT.

44A few trials have targeted ROS. NXY-059 targeting ROS was trialed to reduced alteplase-related intracranial hemorrhages. In animal studies, NXY-059 was associated with improved functional recovery and reduced infarction size. In the human trial, NXY-059 was found to be ineffective for preventing HT. Additionally, as part of a retrospective study in Japan, Edaravone administration with alteplase (rtPA) found that there may be a benefit in early stroke outcome. Edaravone suppresses ROS, inhibits vascular endothelial injuries, and protects the neurovascular unit. No benefit was found for HT occurrence.

45Neutrophils are one of the first innate immune cells to reach the ischemic brain tissue. Neutrophils contribute to injury through inflammatory mediators and damage the BBB through the release of proteolytic enzymes, ROS, and interactions with the endothelium of cerebral blood vessels. In addition, neutrophils accumulate in higher numbers in regions of HT and correlate with disruption of the basal lamina. In experimental stroke studies, depletion of circulating neutrophils reduces thrombolysis-related hemorrhage. In 846 patients treated with thrombolysis, an increased neutrophil to leukocyte (NIL) ratio was independently associated with HT.

46Neutrophils produce neutrophil extracellular traps (NETs), which can promote clot formation associated with resistance to thrombolysis. In cultured human neutrophils, incubation with alteplase induced neutrophil degranulation and an increase in MMP-9 activity in a dose-dependent manner. This may elevate the number of activated neutrophils, thus exacerbating the detrimental effects of neutrophils on the BBB to promote HT. In mice with circulating leukocytes from MMP-9 null bone marrow, BBB disruption was decreased.

47Leukocytes enter the parenchyma and adhere to the cells largely through adhesion molecules ICAM-1, P-selectin, E-selectin, and VCAM-1. Cytokines released by cerebral ischemia such as TNF, IL-1, and IFN-γ up-regulate ICAM-1 on both cerebral endothelial cells and leukocytes. Leukocytes adhering the endothelium can block erythrocytes in the microvasculature, leading to further injury. Activated leukocytes can also lead to secondary injury by producing proteases, MMPs, and ROS that can disrupt blood vessels. Leukocyte derived MMP-9s are mediators of early HT. Leukocyte adhesion and migration across the vasculature activates a number of signaling cascades (protein kinase C, focal adhesion kinase) that increase the BBB permeability. Once in the CNS, activated leukocytes release inflammatory cytokines at the site of injury such as TNF, IL-1β, and IL-6.

48In both rat and rabbit models, treated with alteplase plus N-tert-butyl-α-phenylnitrone (PBN) vs. alteplase alone, PBN was found to attenuate alteplase-induced HT. PBN is a spin trap agent, targeting ROS from leukocytes.

49In both patient and animal studies, the peripheral immune response in ischemic stroke can be characterized by RNA expression in circulating leukocytes. Using leukocyte RNA obtained before thrombolysis treatment in 44 patients with acute stroke (33 with HT), microarray gene expression studies have identified 6 genes that predict the occurrence of HT with 80% sensitivity and 70% specificity. The six-gene panel in Table 8 highlights differences in inflammation and coagulation processes. Factors involved in HT of human stroke include a shift in growth factor-beta signaling involving SMAD4, INPP5D, and IRAK3, a disruption of coagulation factors V and VIII, and amphiregulin, a growth factor-beta that regulates MMP-9. Additionally, increased expression of AKAP7 in peripheral lymphocytes is linked to post stroke complications and BBB permeability. Genes associated with increased HT and mortality risk include two single nucleotide polymorphisms rs669 in α-2-macroglobulin (A2M) and rs1801020 in coagulation Factor XII. Factors associated with the efficacy of alteplase include low fibrin levels and polymorphism of Factor XIII V/V genotype.

50The Genot-PA score, to predict HT in patients treated with alteplase, considered both genetics and clinical variables to establish patient risk. In the trial, 1,324 patients in a Spanish population, were risk-stratified and treated with either alteplase or a combination of alteplase and mechanical thrombectomy. The study was able to predict HT in patients treated with alteplase. External validation of the score is pending.

51Inflammation contributes to BBB disruption and risk of HT, through an increase in ROS, MMPs and neutrophil activation. Clinical factors associated with inflammation and HT include hypertension, hyperglycemia, and age. Diabetes and hypertension lead to structural and functional changes of the neurovascular unit, alter collaterals, and elevate MMP-9, ROS, and proinflammatory cytokines (TNF, IL-1β, and IL-6). Advancing age is associated with a chronic elevation of inflammatory cytokine levels and changes in inflammatory response. These inflammatory markers provide insight to how clinical factors may increase the risk of HT. They may represent novel targets to reduce the risk of HT.

52Further studies of the immune system and inflammation will be useful to better understand the risk of HT associated with reperfusion following thrombolysis and EVT and determine if modulation of the immune system could be useful to prevent HT. With increased use of reperfusion therapy and extension of eligibility criteria (e.g., inclusion of older patients, extended time windows), the importance of preventing HT will become more apparent. An improved safety profile with lower risk of HT could permit more widespread use of reperfusion therapy and greatly affect patients with stroke. Incorporating clinical features, genetics, biomarkers, and imaging to identify patients at risk for HT may help develop novel therapies to prevent HT in stroke.

53All authors meet the authorship criteria and contributed substantially to conception and design or acquisition of data (ES and GJ), or analysis and interpretation of data (all authors), drafted (ES) or revised (all authors) and gave final approval of the version to be published (all authors).

54The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.